VentricHealth

Media Kit

Media & Conference Resources

www.ventrichealth.com



About Ventric Health

- Founded in 2014 and headquartered in Pasadena, California.
- Developing solutions to easily and non-invasively assess cardiovascular health.
- Moving heart failure testing out of specialty clinics and hospitals, and into primary care and home settings.

Bringing heart failure diagnosis into primary care



| © 2026 Ventric Health. All rights reserved.

Our Mission & Vision

Our Mission

To create non-invasive heart diagnostic solutions that quickly deliver the insights clinicians and value-based care organizations need to improve patient lives and reduce avoidable costs.

Our Vision

To bring non-invasive cardiovascular testing to everyone.

Non-invasive insight for earlier heart failure detection.

Ventric Health is solving delays in heart failure diagnosis by giving clinicians access to new, scientifically grounded cardiovascular data that supports earlier and more confident diagnosis. By making advanced, non-invasive testing available beyond traditional specialty settings, **we help care teams identify risk sooner and take action earlier.**

| © 2026 Ventric Health. All rights reserved.


The Origin Story

Ventric Health's origins are academic.

Founded in 2014, Ventric Health was born from breakthrough cardiovascular research at the California Institute of Technology (**Caltech**).

The Vivio System technology emerged from the laboratory of Professor Mory (Morteza) Gharib, with postdoctoral fellows Niema Pahlevan and Derek Rinderknecht.

Vivio is the first and only device to enable non-invasive diagnosis of heart failure within an outpatient and home health care environment.



WATCH VIDEO

| © 2026 Ventric Health. All rights reserved.

The Problem

Heart failure is difficult to diagnose early

- Heart failure affects approximately 6.7 million Americans over 20 years of age.[1]
- Yet most patients are first diagnosed in the emergency room, after the disease has already advanced.[2,3]
- The Vivio® System brings the first and only non-invasive hemodynamic measurement to primary care, closing the diagnostic gap before a crisis occurs.



The lifetime risk of heart failure (HF) is 1 in 4 people.[1]

1. Bozkurt, Biykem. "HF stats 2024: Heart Failure Epidemiology and Outcomes Statistics an updated 2024 report from the Heart Failure Society of America." Journal of Cardiac Failure, vol. 31, no. 1, Jan. 2025, pp. 66–116, https://doi.org/10.1016/j.cardfail.2024.07.001.
2. Cuthbertson CC, Heiss G, Wright JD, et al. Socioeconomic status and access to care and the incidence of a heart failure diagnosis in the inpatient and outpatient settings. Annals of Epidemiology. 2018;28(6):350-355. doi:https://doi.org/10.1016/j.annepidem.2018.04.003.
3. Hayhoe B, Kim D, Aylin PP, Majeed FA, Cowie MR, Bottle A. Adherence to guidelines in management of symptoms suggestive of heart failure in primary care. Heart. 2018;105(9):678-685. doi:https://doi.org/10.1136/heartjnl-2018-313971.

| © 2026 Ventric Health. All rights reserved.

The Solution: Vivio

- FDA-cleared Class II medical device with over 55,000 real-world patients screened
- 3-minute non-invasive test right in the PCP's exam room
- Accurately identifies elevated LVEDP – the clinical hallmark of heart failure
- Supports compliant diagnosis of heart failure in the primary care setting



| © 2026 Ventric Health. All rights reserved.

Fast Facts

FDA-CLEARED
Class II medical device for non-invasive assessment of elevated LVEDP.


3-MINUTE TEST
Non-invasive cardiovascular assessment performed right in the exam room.

REAL-TIME RESULTS
Results are available during the patient encounter.

OBJECTIVE HEMODYNAMIC DATA
Directly identifies elevated LVEDP — a clinical hallmark of heart failure.

PRIMARY CARE ACCESS
Brings advanced cardiovascular assessment beyond traditional specialty and hospital settings.

55,000+ PATIENTS SCREENED
Vivio has been used in real-world clinical settings across the country.



| © 2026 Ventric Health. All rights reserved.

Clinically Validated

In a multicenter prospective U.S. validation study of **728 patients** undergoing left heart catheterization, Vivio demonstrated:

80% SENSITIVITY
83% SPECIFICITY

for identifying elevated LVEDP, using invasive catheter measurements as the reference standard.

More recent primary-care research involving **2,040 high-risk patients** found that **38.5% had elevated LVEDP**, highlighting the potential to uncover previously unrecognized cardiovascular disease in patients with heart-failure risk factors.

A 2026 multicenter study across **25 primary care sites** further demonstrated the scalability of a streamlined Vivio screening workflow, with a **92.2% conclusive diagnostic rate** among 1,238 high-risk patients.

Source: *Journal of the American Heart Association (JAHA)* (December 2025 / January 2026)




VentricHealth

| © 2026 Ventric Health. All rights reserved.

Clinical Evidence

Peer-Reviewed Research on Non-Invasive LVEDP Detection


The evidence base spans peer-reviewed validation studies, multicenter practical trials, and independent clinical recognition — demonstrating not only that Vivio's non-invasive approach correlates with invasive LVEDP measurement, but that it performs reliably at scale, in real-world primary care and population-health settings.



JAHA MULTICENTER VALIDATION STUDY



JACC NONINVASIVE SCREENING FOR ELEVATED LVEDP STUDY



NEW PEER-REVIEWED STUDY UNDERSCORES VIVIO'S CLINICAL UTILITY

View these and additional clinical evidence behind the Vivio System at ventrichealth.com/evidence.

| © 2026 Ventric Health. All rights reserved.

Who We Are

Leadership

- Ventric Health is helmed by servant leaders from diverse backgrounds who are as committed to building a positive corporate culture as they are to transforming cardiovascular care.
- Together, they bring the vision, experience, and drive to turn meaningful innovation into real-world impact.






Get to know our leaders at ventrichealth.com/about-us/#leadership.

| © 2026 Ventric Health. All rights reserved.

Leadership



Sean Brady

Chief Executive Officer, Founder

Sean Brady, Co-founder and Chief Executive Officer, leads strategy, commercial growth and fundraising. He is driving the company's expansion into new clinical applications and markets, while building the partnerships and infrastructure needed to scale.

With a J.D. from NYU School of Law and experience in technology licensing at Caltech, Sean brings a distinctive blend of legal expertise and entrepreneurial execution to medtech. He has led multidisciplinary teams across software, clinical and regulatory functions, guiding Vivio from university research through FDA clearance and into multi-state deployment.

Sean is focused on advancing earlier diagnosis to improve patient outcomes.

| © 2026 Ventric Health. All rights reserved.

Leadership



Derek Rinderknecht

Chief Technical Officer, Founder

Derek Rinderknecht, PhD is Founder and Chief Technology Officer, where he oversees clinical and technical strategy, including research and development, data science and algorithm engineering. He is responsible for advancing the company's diagnostic platform to enable earlier detection of heart failure and expand access to cardiovascular care through innovative, noninvasive technologies.

He led the development and validation of Ventric Health's heart failure algorithm and specializes in translating complex clinical and technical challenges into practical diagnostic solutions.

With more than two decades of experience in biomedical engineering and healthcare technology, Dr. Rinderknecht has worked across cardiovascular monitoring, nanotechnology, drug delivery and diagnostic innovation. He is the inventor of two FDA-cleared medical devices and holds more than 12 patents.

| © 2026 Ventric Health. All rights reserved.

Leadership



Morteza Gharib

Founder

Morteza Gharib, PhD is Co-founder and a Member of the Board of Directors, where he helps guide innovation strategy and provides oversight on the company's scientific and technical direction. He is focused on expanding access to advanced diagnostic technologies, particularly for populations underserved by early detection tools.

Dr. Gharib is a leader in medical device innovation and translational engineering, with extensive experience advancing technologies from academic research into clinical and commercial applications. He holds more than 200 U.S. patents and has co-founded several successful life sciences and medical technology companies, including Glaukos Corporation and Argus Imaging.

Dr. Gharib is a member of the American Academy of Arts and Sciences and the National Academy of Engineering, and a Fellow of multiple leading scientific and engineering organizations.

| © 2026 Ventric Health. All rights reserved.

Leadership



Niema Pahlevan

Founder

Niema Pahlevan, PhD is Co-founder, where he contributes to the company's scientific and clinical innovation, applying expertise in cardiovascular biomechanics and hemodynamics to advance noninvasive diagnostic technologies.

Dr. Pahlevan is a biomedical engineer and cardiovascular scientist with more than a decade of experience developing medical technologies. He is a tenured Associate Professor at the University of Southern California, with joint appointments in Aerospace and Mechanical Engineering and in Medicine (Division of Cardiovascular Medicine).

He is a Fellow of the American Heart Association and a Senior Member of the National Academy of Inventors and is committed to translating engineering advances into practical solutions that improve heart failure care.

| © 2026 Ventric Health. All rights reserved.

Who We Are

Advisory Board

- Ventric Health's Advisory Board brings together leading experts in cardiology, outcomes research, market access and health technology to guide the company's clinical and commercial strategy.

- Their collective expertise helps ensure that Ventric Health's solutions are grounded in clinical evidence, aligned with real-world care pathways and positioned for successful adoption across the healthcare market.

Get to know our advisors at ventrichealth.com/about-us/#advisors.







| © 2026 Ventric Health. All rights reserved.

Advisory Board



Javeed Butler

MD, MPH, MBA

Javed Butler, MD, MPH, MBA is a board-certified cardiologist and internationally recognized leader in heart failure and cardiovascular research. He is the President of the Baylor Scott and White Research Institute and Senior Vice President for the Baylor Scott and White Health in Dallas, Texas. He currently holds the Maxwell A. and Gayle H. Clampitt Endowed Chair for research. He is also the Distinguished Professor of Medicine at University of Mississippi in Jackson, Mississippi. He has also served as the director for heart failure research at Emory University and director of the heart and heart-lung transplant programs at Vanderbilt University.

His research interests focus on clinical trials in patients with heart failure. He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He has authored more than 1500 peer-reviewed publications and also serves on the editorial board of several peer reviewed cardiovascular journals.

| © 2026 Ventric Health. All rights reserved.

Advisory Board



Biykem Bozkurt

MD, PhD, FHFSA, FACC, FAHA, FACP

Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP is leading expert in heart failure and cardiovascular medicine, with a distinguished career spanning clinical care, research and academic leadership. She serves as Senior Dean of Faculty and Professor of Medicine at Baylor College of Medicine, where she also leads the Winters Center for Heart Failure.

Dr. Bozkurt is an advanced heart failure and cardiac transplantation specialist and has held numerous leadership roles in major cardiovascular organizations, including serving as President of the Heart Failure Society of America and contributing to national heart failure guidelines. She currently serves as Editor-in-Chief of JACC: Heart Failure and is widely recognized for her contributions to advancing heart failure care through clinical research and guideline development.

| © 2026 Ventric Health. All rights reserved.

Advisory Board



KellyAnn Light-McGroary

MD, MHCDS, FSCC

KellyAnn Light-McGroary, MD, MHCDS, FSCC is a Heart Failure and Transplant Cardiologist at University of Iowa Health Care and founder of KALM Healthcare Consulting. With over 30 years of clinical and healthcare leadership experience, she partners with private and government sector clients on strategy development, quality improvement and identifying opportunities that drive better outcomes for patients and communities.

| © 2026 Ventric Health. All rights reserved.

Advisory Board



John Spertus

MD, MPH, FACC

John Spertus, MD, MPH, FACC is a board-certified cardiologist and Clinical Director of Outcomes Research at Saint Luke's Mid America Heart Institute, where he also holds the Lauer Missouri Endowed Chair and Professor of Medicine at the University of Missouri–Kansas City. His research focuses on personalized medicine, measuring healthcare quality and leveraging information technology to guide clinical decision-making.

| © 2026 Ventric Health. All rights reserved.

Advisory Board



Erik Abel

PharmD, MBA

Erik Abel, PharmD, MBA is a clinical and commercial healthcare executive and founder of OneAnother Health, LLC, with experience spanning AI-enabled diagnostics, digital health, and market access. He has led a nine-figure acquisition by GE HealthCare and deployed a national AI diagnostic service across 40+ states. Drawing on experience on both sides of the healthcare value chain, including payer transformation at Highmark Health and provider system transformation at Ohio State University, he advises startups and investors on evidence, reimbursement, and commercialization.

| © 2026 Ventric Health. All rights reserved.

Downloadable Media Assets

Leadership & Advisory Board Headshots


Vivio System Product Imagery

Ventric Health Logos

Brand Style Guide

Product Literature

Peer-Reviewed Evidence



| © 2026 Ventric Health. All rights reserved.

Video Resources



Hello Vivio: The heart failure detection problem and solution explained.

3-minute non-invasive monitoring | 2:23 overview

WATCH VIDEO



Demo: Vivio System Heart Failure Diagnosis in the clinical setting.

Capturing LVEDP in real time | 1:40 overview

WATCH VIDEO

| © 2026 Ventric Health. All rights reserved.

Media Contact

For press and media inquiries:

press@ventrichealth.com

117 E Colorado Blvd., Suite 510,
Pasadena, CA 91105



| © 2026 Ventric Health. All rights reserved.

Disclaimers

The Vivio System is available only in the United States.

This information is intended for medical and healthcare media professionals.

Vivio is a registered trademark of Ventric Health. All rights reserved.

| © 2026 Ventric Health. All rights reserved.